课题基金 / 基金详情

SAFETY AND TOLERANCE OF CHRONIC NEVIRAPINE DOSING IN HIV 1 INFECTED CHILDREN

SAFETY AND TOLERANCE OF CHRONIC NEVIRAPINE DOSING IN HIV 1 INFECTED CHILDREN
HIV 1 感染儿童长期服用奈韦拉平的安全性和耐受性
批准号：
6309829
负责人：
Peter James Krause
金额：
$1.91万
依托单位：
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6309829
关键词：
2'3' dideoxyinosine AIDS therapy HIV infections child (0-11) clinical research combination chemotherapy dosage drug screening /evaluation drug tolerance human subject human therapy evaluation longitudinal human study nevirapine oral administration pediatric AIDS zidovudine

项目摘要

项目成果

Peter James Krause的其他基金

相似基金

相关文献

中文摘要
翻译
这项多地点的II期开放标签临床试验是由勃林格殷格翰公司赞助的。该试验旨在评估多剂量口服奈韦拉平（单独使用和与AZT和ddI联合使用）的长期安全性和耐受性。注册的孩子必须成功完成ACTG 180。长期服用奈韦拉平的受试者效果良好。本研究不接受登记。
英文摘要
This multi-site phase II, open label clinical trial of the ACTG (AIDS Clinical Trial Groups) is sponsored by Boehringer Ingelheim. It is designed to assess the long-term safety and tolerance of multiple oral doses of Nevirapine (alone and in combination with AZT and ddI). The children enrolled must have successfully completed ACTG 180. Subjects continuing on long-term Nevirapine are doing well. This study is closed to enrollment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RECURRENT LYME DISEASE
RECURRENT LYME DISEASE
RECURRENT LYME DISEASE
Recurrent Lyme Disease
海外基金